Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non–small-cell lung cancers
Background Epidermal growth factor receptor (EGFR) is often overexpressed in non–small-
cell lung cancer (NSCLC). Anti-EGFR agents, including EGFR-tyrosine kinase inhibitors are …
cell lung cancer (NSCLC). Anti-EGFR agents, including EGFR-tyrosine kinase inhibitors are …
[HTML][HTML] Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3
J Yue, D Lv, C Wang, L Li, Q Zhao, H Chen, L Xu - Oncogene, 2018 - nature.com
All lung cancers patients with epidermal growth factor receptor (EGFR) mutation inevitably
develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI). In up to 30% of cases …
develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI). In up to 30% of cases …
[HTML][HTML] Potential resistance mechanisms revealed by targeted sequencing from lung adenocarcinoma patients with primary resistance to epidermal growth factor …
J Zhong, L Li, Z Wang, H Bai, F Gai, J Duan… - Journal of Thoracic …, 2017 - Elsevier
Introduction EGFR tyrosine kinase inhibitors (TKIs) have greatly improved the prognosis of
lung adenocarcinoma. However, approximately 5% to 10% of patients with lung …
lung adenocarcinoma. However, approximately 5% to 10% of patients with lung …
[HTML][HTML] LINC00665 induces acquired resistance to gefitinib through recruiting EZH2 and activating PI3K/AKT pathway in NSCLC
X Liu, X Lu, F Zhen, S Jin, T Yu, Q Zhu, W Wang… - … Therapy-Nucleic Acids, 2019 - cell.com
Gefitinib, a tyrosine kinase inhibitor of epidermal growth factor receptor, has been used as
the first choice of treatment for advanced non-small-cell lung cancer. However, during the …
the first choice of treatment for advanced non-small-cell lung cancer. However, during the …
[HTML][HTML] Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
EGFR tyrosine kinase inhibitor (TKI) resistance in non-small cell lung cancer (NSCLC)
patients is inevitable. Identification of resistance mechanisms and corresponding targeting …
patients is inevitable. Identification of resistance mechanisms and corresponding targeting …
[HTML][HTML] Plasma microRNA alterations between EGFR-activating mutational NSCLC patients with and without primary resistance to TKI
Y Ma, X Pan, P Xu, Y Mi, W Wang, X Wu, Q He, X Liu… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have obtained
excellent therapeutic effects against non-small cell lung cancer (NSCLC) harboring …
excellent therapeutic effects against non-small cell lung cancer (NSCLC) harboring …
Multiple post-translational modifications ensure EGFR functionality: Potential therapeutic targets to overcome its drug-resistance mutations
Q He, M Qu, H Bao, Y Xu, T Shen, D Tan… - Cytokine & Growth …, 2023 - Elsevier
Epidermal growth factor receptor (EGFR) mutation is the most common driver mutation in
non-small cell lung cancer (NSCLC). The first-line therapy for advanced NSCLC patients …
non-small cell lung cancer (NSCLC). The first-line therapy for advanced NSCLC patients …
Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy
Motivation: Non–small-cell lung cancer (NSCLC) is the leading cause of cancer death in the
United States. Targeted tyrosine kinase inhibitors (TKIs) directed against the epidermal …
United States. Targeted tyrosine kinase inhibitors (TKIs) directed against the epidermal …
[HTML][HTML] Altered expression of cellular proliferation, apoptosis and the cell cycle-related genes in lung cancer cells with acquired resistance to EGFR tyrosine kinase …
TG Lee, EH Jeong, IJ Min, SY Kim… - Oncology …, 2017 - spandidos-publications.com
Non-small cell lung cancers harboring somatic gain-of-function mutations in the epidermal
growth factor receptor (EGFR) tyrosine kinase domain respond well to treatment with EGFR …
growth factor receptor (EGFR) tyrosine kinase domain respond well to treatment with EGFR …
Long noncoding RNA LINC00460 promotes the gefitinib resistance of nonsmall cell lung cancer through epidermal growth factor receptor by sponging miR-769-5p
G Ma, J Zhu, F Liu, Y Yang - DNA and cell biology, 2019 - liebertpub.com
The vital roles of long noncoding RNAs (lncRNAs) in the nonsmall cell lung cancer (NSCLC)
tumorigenesis are increasingly important. This work aims to investigate the role of lncRNA …
tumorigenesis are increasingly important. This work aims to investigate the role of lncRNA …